Lineage Cell Therapeutics, Inc. (LCTX)

Market Cap	112.33M
Revenue (ttm)	9.50M
Net Income (ttm)	-18.61M
Shares Out	228.36M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,337,933
Open	0.4990
Previous Close	0.5000
Day's Range	0.4811 - 0.4990
52-Week Range	0.4700 - 1.6100
Beta	1.28
Analysts	Strong Buy
Price Target	4.20 (+753.83%)
Earnings Date	Mar 10, 2025

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 77
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: LCTX
• Website: https://www.lineagecell.com

Financial Performance

In 2024, Lineage Cell Therapeutics's revenue was $9.50 million, an increase of 6.19% compared to the previous year's $8.95 million. Losses were -$18.61 million, -13.39% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for LCTX stock is "Strong Buy." The 12-month stock price forecast is $4.2, which is an increase of 753.83% from the latest price.

Price Target

$4.2

(753.83% upside)

Analyst Consensus: Strong Buy